natgillin/translations-raw huggingface dataset:
- if you have Parkinson's disease - if you have ever been diagnosed with a condition whose symptoms include high temperature and muscle stiffness (also known as Neuroleptic Malignant Syndrome) - if you have ever experienced twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body (Tardive Dyskinesia) - if you know that you have had low levels of white blood cells in the past (which may or may not have been caused by other medicines) - if you are diabetic or prone to diabetes - if you have had breast cancer or a tumour in the pituitary gland in your brain - if you have a heart disease or heart disease treatment that makes you prone to low blood pressure - if you have low blood pressure when you stand up or sit up suddenly - if you have a history of seizures - if you have kidney problems - if you have liver problems - if you have prolonged and/or painful erection - if you have problems with controlling body temperature or overheating - if you have an abnormally high level of the hormone prolactin in your blood or if you have a possible prolactin-dependent tumour - if you or someone else in your family has a history of blood clots, as antipsychotics have been associated with formation of blood clots.
- če imate Parkinsonovo bolezen - če so vam kdaj diagnosticirali stanje s simptomi, kot sta povišana telesna temperatura in mišična okorelost (znano tudi kot nevroleptični maligni sindrom) - če so se pri vas kadar koli pojavili sunkoviti gibi ali trzljaji obraza, jezika ali drugih delov telesa, ki jih niste mogli nadzorovati (tardivna diskinezija) - če ste že imeli majhno število belih krvnih celic (ki bi jo lahko ali ne povzročilo drugo zdravilo) - če imate sladkorno bolezen ali ste nagnjeni k sladkorni bolezni - če ste imeli raka dojke ali tumor hipofize v možganih - če imate srčno bolezen ali se zdravite za srčne bolezni in ste zato nagnjeni k nizkemu krvnemu tlaku - če imate nizek krvni tlak, kadar nenadoma vstanete ali se usedete iz ležečega položaja - če ste imeli epileptične krče - če imate težave z ledvicami - če imate težave z jetri - če imate podaljšano in/ali bolečo erekcijo - če imate težave z nadzorovanjem telesne temperature ali se hitro pregrejete - če imate nenormalno visoke koncentracije hormona prolaktina v krvi ali imate tumor, ki je odvisen od prolaktina - če ste imeli vi ali kdo drug v vaši družini krvne strdke, saj je jemanje antipsihotikov povezano z nastankom krvnih strdkov
Patients treated with TREVICTA should be monitored for symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus should be monitored regularly for worsening of glucose control.
Bolnike, ki prejemajo zdravilo TREVICTA, je treba spremljati glede simptomov hiperglikemije (kot so polidipsija, poliurija, polifagija in šibkost) ter redno spremljati bolnike s sladkorno boleznijo glede poslabšanja nadzora koncentracije glukoze v krvi.
Following the initial TREVICTA dose, TREVICTA should be administered by intramuscular injection once every 3 months (± 2 weeks, see also Missed dose section).
Po začetnem odmerku zdravila TREVICTA je treba zdravilo injicirati intramuskularno enkrat na 3 mesece (± 2 tedna, glejte tudi poglavje Izpuščeni odmerki).
If needed, dose adjustment of TREVICTA can be made every 3 months in increments within the range of 175 mg to 525 mg based on individual patient tolerability and/or efficacy.
Po potrebi se lahko odmerke zdravila TREVICTA postopno prilagaja vsake 3 mesece v razponu odmerkov od 175 mg do 525 mg, odvisno od prenašanja in/ali učinkovitosti zdravila pri posameznem bolniku.
• have dementia and experience a sudden change in your mental state or sudden weakness or numbness of your face, arms or legs, especially on one side, or slurred speech, even for a short period of time.
• imate demenco in opazite nenadne spremembe svojega duševnega stanja ali nenadno šibkost ali odrevenelost obraza, rok ali nog, zlasti če se to pojavi samo na eni strani telesa, ali nerazločnost govora, četudi samo za kratek čas.
Do not administer by any other route.
Ne injicirajte na noben drug način.
Seek medical attention right away if you experience a rash, swelling of your throat, itching, or problems breathing as these may be signs of a serious allergic reaction.
Če opazite izpuščaj, vam oteče grlo, vas srbi ali imate težave z dihanjem, takoj poiščite zdravniško pomoč, ker so to lahko znaki hude alergijske reakcije.
The most frequently observed adverse drug reactions reported in ≥ 5% of patients in two double-blind controlled clinical trials of TREVICTA were weight increased, upper respiratory tract infection, anxiety, headache, insomnia, and injection site reaction.
Najpogostejši neželeni učinki, o katerih so poročali pri ≥ 5% bolnikov v dveh dvojno slepih nadzorovanih kliničnih preskušanjih zdravila TREVICTA, so bili povečanje telesne mase, okužba zgornjih dihal, tesnoba, glavobol, nespečnost in reakcija na mestu injiciranja zdravila.
Do not save for future use.
Ne smete je shraniti za kasnejšo uporabo.
Regardless of patient weight: yellow hub
Neodvisno od bolnikove telesne mase: rumeni nastavek
The difference (95% CI) between the treatment groups was 1.2% (-2.7%, 5.1%), meeting non-inferiority criterion based on a margin of -10%.
Ta odstotek se je med skupinama razlikoval za 1,2% (95-odstotni interval zaupanja -2, %, 5,1%), s čimer je bil izpolnjen kriterij za neinferiornost, ki ga je določal prag razlike -10%.
Paliperidone is not expected to cause clinically important pharmacokinetic interactions with medicinal products that are metabolised by cytochrome P450 isozymes.
Ni pričakovati, da bi paliperidon povzročil klinično pomembne farmakokinetične interakcije z zdravili, ki se presnavljajo z izoencimi citokroma P450.
TREVICTA should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold.
Zdravilo TREVICTA je treba uporabljati previdno pri bolnikih z epileptičnimi napadi v anamnezi ali z drugimi stanji, ki lahko znižajo prag za epileptični napad.
Potential for TREVICTA to affect other medicines
Možnost, da bo zdravilo TREVICTA vplivalo na druga zdravila
Dizziness, extreme tiredness and vision problems may occur during treatment with this medicine (see section 4).
Med zdravljenjem s tem zdravilom se lahko pojavijo omotica, izčrpanost in težave z vidom (glejte poglavje 4).
Consideration should be given to the long-acting nature of TREVICTA.
Upoštevati je treba podaljšano delovanje zdravila TREVICTA.
Slowly inject the entire contents of the syringe intramuscularly, deep into the selected deltoid or gluteal muscle.
Celotno vsebino injekcijske brizge intramuskularno injicirajte počasi, globoko v izbrano deltoidno ali glutealno mišico.
The primary efficacy endpoint of the study was the percentage of subjects who had not relapsed at the end of the 48-week double-blind phase based on the Kaplan-Meier 48-week estimate (TREVICTA: 91.2%, 1-monthly paliperidone palmitate injectable: 90.0%).
Primarni cilj učinkovitosti v študiji je bil odstotek preiskovancev, pri katerih do konca 48-tedenskega obdobja dvojno slepega zdravljenja ni prišlo do relapsa na osnovi Kaplan-Meierjeve ocene v 48 tednih (zdravilo TREVICTA: 91,2%, 1-mesečne injekcije paliperidonijevega palmitata: 90,0%).
On initiation of carbamazepine, the dose of TREVICTA should be re-evaluated and increased if necessary.
Ob uvajanju karbamazepina je treba odmerek zdravila TREVICTA ponovno oceniti in ga po potrebi povečati.
The dose could be adjusted (i.e., 50 mg, 75 mg, 100 mg, or 150 mg) at the week 5 and 9 injections and the injection site could be deltoid or gluteal.
Odmerke so lahko prilagajali (50 mg, 75 mg, 100 mg ali 150 mg) ob injiciranju zdravila v 5. in po 9. tednu, injicirali pa so jih v deltoidno ali glutealno mišico.
Conversely, on discontinuation of carbamazepine, the dose of TREVICTA should be re-evaluated and decreased if necessary.
Ob ukinitvi karbamazepina je treba odmerek zdravila TREVICTA ponovno oceniti in po potrebi zmanjšati.
They were either derived from spontaneous post-marketing reports and frequency cannot be determined, or they were derived from risperidone (any formulation) or oral paliperidone clinical trials data and/or post-marketing reports.
Izhajajo iz spontanih poročil v obdobju po prihodu zdravila na trg in njihove pogostnosti ni mogoče določiti, ali iz podatkov kliničnih preskušanj in/ali poročil v obdobju po prihodu zdravila na trg z risperidonom (katera koli oblika) ali paliperidonom v peroralni obliki.
In a study with oral paliperidone in subjects with moderate hepatic impairment (Child-Pugh class B), the plasma concentrations of free paliperidone were similar to those of healthy subjects.
V študiji peroralnega paliperidona pri preiskovancih z zmerno okvaro jeter (razred B po Child-Pughovi lestvici) so bile koncentracije prostega paliperidona v plazmi podobne kot pri zdravih preiskovancih.
The efficacy of TREVICTA in the maintenance treatment of schizophrenia in subjects who have been adequately treated for at least four months with 1-monthly paliperidone palmitate injectable and the last two doses of the same dosage strength was evaluated in one long-term randomised withdrawal double-blind, placebo-controlled study and one long-term double-blind, active-controlled, non-inferiority study.
Učinkovitost zdravila TREVICTA za vzdrževalno zdravljenje shizofrenije pri bolnikih, ki so bili najmanj štiri mesece ustrezno zdravljeni z 1-mesečnimi injekcijami paliperidonijevega palmitata (in sta bila zadnja dva odmerka iste jakosti), so ocenjevali v eni dolgotrajni, randomizirani, dvojno slepi, s placebom nadzorovani študiji odtegnitve zdravila in drugi, dolgotrajni, dvojno slepi, aktivno nadzorovani študiji za oceno neinferiornosti zdravila.
Effect of smoking on the pharmacokinetics of paliperidone was not studied with TREVICTA.
Vpliva kajenja na farmakokinetiko paliperidona pri uporabi zdravila TREVICTA niso preučevali.
Subjects who were considered clinically stable at the end of the 12-week stabilisation phase were then randomised 1:1 to TREVICTA or placebo in a variable duration double-blind phase (the dose of TREVICTA was the same as the last dose received during the stabilisation phase; this dose remained fixed throughout the double-blind phase).
Bolnike, ki so jih po koncu 12-tedenske faze stabilizacije ocenili kot klinično stabilne, so nato randomizirali v razmerju 1:1 na prejemanje zdravila TREVICTA ali placeba v obdobju dvojno slepega zdravljenja z različnim trajanjem (odmerek zdravila TREVICTA je bil enak zadnjemu prejetemu odmerku v fazi stabilizacije in se ni spremenil celotno obdobje dvojno slepega zdravljenja).
Switching from TREVICTA to other antipsychotic medicinal products If TREVICTA is discontinued, its prolonged release characteristics must be considered.
Prehod z zdravila TREVICTA na drugo antipsihotično zdravilo Ob ukinitvi zdravila TREVICTA je treba upoštevati njegovo podaljšano delovanje.
• sensation of spinning (vertigo), ringing in the ears, ear pain
• vrtoglavica (občutek vrtenja), zvonjenje v ušesih, bolečina v ušesu
Medicinal products with dopamine receptor antagonistic properties have been associated with the induction of tardive dyskinesia characterised by rhythmical, involuntary movements, predominantly of the tongue and/or face.
Zdravila z antagonističnim delovanjem na dopaminske receptorje so povezana z razvojem tardivne diskinezije, za katero so značilni ritmični, nehoteni gibi, predvsem jezika in/ali obraza.
Dispose properly
Pripomočke pravilno zavrzite
Total clearance of paliperidone was reduced in subjects with impaired renal function by 32% on average in mild (CrCl = 50 to < 80 mL/min), 64% in moderate (CrCl = 30 to < 50 mL/min), and 71% in severe (CrCl = 10 to < 30 mL/min) renal impairment, corresponding to an average increase in exposure (AUCinf) of 1.5, 2.6, and 4.8-fold, respectively, compared to healthy subjects.
Celokupni očistek paliperidona se je pri preiskovancih z okvaro ledvic v povprečju zmanjšal za 32% pri blagi okvari ledvic (CrCl = 50 do < 80 ml/min), za 64% pri zmerni (CrCL = 30 do < 50 ml/min) in za 71% pri hudi (CrCl = 10 do < 30 ml/min) okvari ledvic, kar je skladno s povprečnim povečanjem izpostavitve (AUCinf) za 1,5-, 2,6- oziroma 4,8-krat v primerjavi z zdravimi preiskovanci.
Patients with severe neutropenia (absolute neutrophil count
Pri bolnikih s hudo nevtropenijo (absolutno število nevtrofilcev < 1 x 10
Based on the final analysis (N = 305), 42 subjects (29.0%) in the placebo group and 14 subjects (8.8%) in the TREVICTA group had experienced a relapse event during the double blind phase.
Na osnovi končne analize (N = 305), je do relapsa med dvojno slepo fazo študije prišlo pri 42 preiskovancih (29,0%) v skupini, ki je prejemala placebo in pri 14 preiskovancih (8,8%) v skupini, ki je prejemala zdravilo TREVICTA.
How to use TREVICTA
Kako uporabljati zdravilo TREVICTA
Missed doses If scheduled dose is missed and the time since last injection is
Izpuščeni odmerki Izpuščeni odmerek in čas, ki je pretekel od zadnje injekcije
To avoid a missed dose of TREVICTA patients may be given the injection up to 2 weeks before or after the 3-month time point.
Da preprečite spuščanje odmerka zdravila TREVICTA, lahko bolnikom zdravilo injicirate do 2 tedna pred 3-mesečnim časovnim rokom ali do 2 tedna po njem.
This interaction has not been studied with TREVICTA.
Te interakcije z zdravilom TREVICTA niso preučevali.
TREVICTA, a 3-monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1-monthly paliperidone palmitate injectable product (see section 5.1).
Zdravilo TREVICTA, 3-mesečna injekcija, je indicirano za vzdrževalno zdravljenje shizofrenije pri odraslih bolnikih, ki so klinično stabilni in so pred tem prejemali 1-mesečne injekcije paliperidonijevega palmitata (glejte poglavje 5.1).
Repeat-dose toxicity studies of intramuscularly injected paliperidone palmitate (the 1-monthly formulation) and orally administered paliperidone in rat and dog showed mainly pharmacological effects, such as sedation and prolactin-mediated effects on mammary glands and genitals.
Študije toksičnosti z večkratnimi odmerki intramuskularno injiciranega paliperidonijevega palmitata (v obliki 1-mesečnih injekcij) in peroralnega paliperidona na podganah in psih so večinoma pokazale farmakološke učinke, kot so sedacija ter učinki prolaktina na mlečne žleze in spolovila.
• tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue,
• tardivna diskinezija (nenadzorovano trzanje in sunkoviti gibi, ki jih ne morete nadzorovati, na obrazu, jeziku ali drugih delih telesa).
Potential for other medicines to affect TREVICTA
Možnost, da bodo druga zdravila vplivala na zdravilo TREVICTA
• a reaction at the injection site, including itching, pain or swelling.
• reakcija ne mestu injiciranja, vključno s srbenjem, bolečino ali otekanjem.
Concomitant use of TREVICTA with risperidone or oral paliperidone
Sočasna uporaba zdravila TREVICTA in risperidona ali peroralnega paliperidona
Due to the long-acting nature of TREVICTA, the patient's response to an adjusted dose may not be apparent for several months (see section 5.2).
Zaradi podaljšanega sproščanja zdravila TREVICTA je bolnikov odziv na spremenjeno odmerjanje lahko opazen šele po več mesecih (glejte poglavje 5.2).
Hold the syringe upright and tap gently to make any air bubbles rise to the top.
Injekcijsko brizgo postavite v pokončen položaj in jo nežno krcnite, da se morebitni zračni mehurčki dvignejo na vrh.
TREVICTA is intended for intramuscular use only.
Zdravilo TREVICTA je namenjeno samo intramuskularni uporabi.
TREVICTA should not be used while breast-feeding.
Zdravila TREVICTA se med dojenjem ne sme uporabljati.
The injection should be administered as soon as possible and then resume the 3-monthly injection schedule.
Injekcijo je treba bolniku dati čim prej, nato pa nadaljevati z odmerjanjem na 3 mesece.
Male rats showed a statistically significant increase in mammary gland adenomas and carcinomas at 30 and 60 mg/kg/month which is 0.6 and 1.2 times the exposure level at the maximum recommended human 525 mg dose.
Pri podganjih samcih so ugotovili statistično značilno povečanje pojavnosti adenomov in karcinomov mlečnih žlez, in sicer pri odmerkih 30 in 60 mg/kg/mesec, kar ustreza 0,6-oziroma 1,2-kratni izpostavljenosti največjemu priporočenemu odmerku pri človeku (525 mg).
Subjects received TREVICTA once every 3 months and received placebo-injectable medication for the other months to maintain the blind.
Preiskovanci, ki so prejemali zdravilo TREVICTA enkrat na 3 mesece, so v preostalih mesecih prejemali injekcije s placebom, tako da je zdravljenje ostalo slepo.
Given the primary central nervous system (CNS) effects of paliperidone (see section 4.8), TREVICTA should be used with caution in combination with other centrally acting medicinal products, e.g., anxiolytics, most antipsychotics, hypnotics, opiates, etc. or alcohol.
Ker paliperidon primarno deluje na osrednje živčevje (glejte poglavje 4.8), je treba zdravilo TREVICTA uporabljati previdno v kombinaciji z drugimi zdravili, ki tudi delujejo na osrednje živčevje, kot so anksiolitiki, večina antipsihotikov, uspavala, opiati in podobno, ali z alkoholom.
TREVICTA has not been studied in patients with renal impairment (see section 5.2).
Zdravila TREVICTA niso preučevali pri bolnikih z okvaro ledvic (glejte poglavje 5.2).
Slowly and carefully press plunger rod upward to remove air.
Počasi in previdno potisnite bat navzgor, da iztisnete zrak.
To avoid incomplete administration of TREVICTA, the pre-filled syringe must be shaken vigorously for at least 15 seconds within 5 minutes prior to administration to ensure a homogeneous suspension (see Information intended for medical or health care professionals).
Da bo odmerek zdravila TREVICTA injiciran v celoti, je treba napolnjeno injekcijsko brizgo 5 minut pred odmerjanjem najmanj 15 sekund močno stresati, da postane suspenzija homogena (glejte Informacije za zdravnike in drugo zdravstveno osebje).
In animals treated with paliperidone palmitate an inflammatory reaction was seen at the intramuscular injection site.
Pri živalih, ki so jim aplicirali paliperidonijev palmitat, so opazili vnetno reakcijo na mestu intramuskularnega injiciranja.
Although TREVICTA was not studied in patients with hepatic impairment, no dose adjustment is required in patients with mild or moderate hepatic impairment.
Čeprav zdravila TREVICTA niso preučevali pri bolnikih z okvaro jeter, pri bolnikih z blago ali zmerno okvaro jeter ni treba prilagajati odmerka.
Paliperidone is excreted in the breast milk to such an extent that effects on the breast-fed infant are likely if therapeutic doses are administered to breast-feeding women.
Paliperidon se izloča v materino mleko v tolikšni meri, da bi verjetno vplival na dojenega otroka, če bi doječa mati prejemala terapevtske odmerke zdravila.
Hypersensitivity reactions can occur even in patients who have previously tolerated oral risperidone or oral paliperidone (see section 4.8).
Preobčutljivostne reakcije se lahko pojavijo tudi pri bolnikih, ki so dobro prenašali peroralni risperidon ali peroralni paliperidon (glejte poglavje 4.8).
Following intramuscular injection of TREVICTA at doses of 175-525 mg in the deltoid muscle, on average, an 11-12% higher Cmax was observed compared with injection in the gluteal muscle.
Po intramuskularnem injiciranju zdravila TREVICTA v odmerkih 175-525 mg v deltoidno mišico so opazili v povprečju za 11-12% višjo Cmax kot pri injiciranju v glutealno mišico.
The combined use of psychostimulants (e.g. methylphenidate) with paliperidone can lead to extrapyramidal symptoms upon change of either or both treatments (see section 4.4).
Kombinirana uporaba psihostimulansov (metilfenidata) in paliperidona lahko ob spremembi enega ali obeh zdravil povzroči ekstrapiramidne simptome (glejte poglavje 4.4).
Figure 2: Kaplan-Meier plot of time to relapse comparing TREVICTA and 1-monthly paliperidone palmitate injectable
Slika 2: Kaplan-Meierjeva krivulja časa do relapsa primerjave zdravila TREVICTA in 1-mesečnih injekcij paliperidonijevega palmitata
• irritability, depression, anxiety
• razdražljivost, depresija, tesnoba
In oral carcinogenicity studies of risperidone in rats and mice, increases in pituitary gland adenomas (mouse), endocrine pancreas adenomas (rat), and mammary gland adenomas (both species) were seen.
V študijah kancerogenosti peroralnega risperidona na podganah in miših so opazili povečano pogostnost adenomov hipofize (pri miših), adenomov endokrinega dela trebušne slinavke (pri podganah) in adenomov mlečnih žlez (pri obeh vrstah).
It is important to only use the needles provided in the TREVICTA pack.
Pomembno je, da uporabljate samo injekcijske igle, ki so priložene pakiranju zdravila TREVICTA.
• an increase of CPK (creatine phosphokinase) in your blood, an enzyme which is sometimes released with muscle breakdown
• povišana koncentracija kreatin fosfokinaze (CPK) v krvi (encima, ki se včasih sprosti ob razpadanju mišic)
Long-acting 3-monthly paliperidone palmitate injection versus other paliperidone formulations
Dolgodelujoče 3-mesečne injekcije paliperidonijevega palmitata v primerjavi z drugimi formulacijami paliperidona
• increased GGT (a liver enzyme called gamma-glutamyltransferase) in your blood, increased liver enzymes in your blood
• povišana koncentracija GGT (jetrnega encima, ki ga imenujemo gama-glutamil transferaza) v krvi, povišana koncentracija jetrnih encimov v krvi
The disposition of a single oral dose of a paliperidone 3 mg prolonged release tablet was studied in subjects with varying degrees of renal function.
Izločanje enkratnega 3 mg odmerka paliperidona v obliki tablet s podaljšanim sproščanjem so preučevali pri preiskovancih z različnimi stopnjami delovanja ledvic.
Then administer TREVICTA (into deltoid a or gluteal muscle)
Nadaljujte z odmerjanjem zdravila TREVICTA (v deltoidno a ali glutealno mišico)
• experience fever, muscle stiffness, sweating or a lowered level of consciousness (a disorder called “Neuroleptic Malignant Syndrome”).
• imate povišano telesno temperaturo, okorele mišice, se potite ali imate zmanjšano stopnjo zavesti (stanje, ki se imenuje nevroleptični maligni sindrom).
logrank test, p-value<0.0001
Ocenjen odstotek bolnikov brez relapsa test log rank, vrednost p<0,0001
Caution should be exercised when paliperidone is prescribed in patients with known cardiovascular disease or family history of QT prolongation, and in concomitant use with other medicinal products thought to prolong the QT interval.
Pri predpisovanju paliperidona bolnikom z znano srčnožilno boleznijo ali s podaljšanjem intervala QT v družinski anamnezi ter pri sočasni uporabi paliperidona z drugimi zdravili, ki tudi podaljšajo interval QT, je potrebna previdnost.
In rat reproduction studies with oral risperidone, which is extensively converted to paliperidone in rats and humans, adverse effects were seen on the birth weight and survival of the offspring.
V študijah reprodukcije pri podganah z uporabo peroralnega risperidona, ki se tako pri podganah kot pri človeku v velikem obsegu pretvarja v paliperidon, so opažali neželene učinke v smislu zmanjšanja porodne teže in preživetja mladičev.
The following table provides recommended dose conversion regimens to allow patients previously stabilised on different doses of TREVICTA to attain similar paliperidone exposure with paliperidone prolonged release tablets.
V preglednici so navedene priporočene sheme odmerjanja, s katerimi lahko bolniki, ki so bili stabilizirani z različnimi odmerki zdravila TREVICTA, dosežejo podobno izpostavljenost paliperidonu tudi s tabletami paliperidona s podaljšanim sproščanjem.
• are aware of having dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood.
• veste, da imate nevarno majhno število določenih tipov belih krvnih celic, ki jih potrebujete za obrambo pred okužbo v krvi.
You will receive an injection of TREVICTA in the upper arm or buttocks once every 3 months.
Zdravilo TREVICTA vam bodo injicirali v nadlaket ali zadnjico enkrat na 3 mesece.